Profile data is unavailable for this security.
About the company
Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It also offers pet care, crop protection solutions, and veterinary care. It offers healthcare solutions for a range of healthcare needs with a portfolio that includes anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/central nervous system, vitamins, minerals and nutrients, derma, fertility, and respiratory therapies. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others. Its subsidiaries include Lifestar Pharma Private Limited, Magnet Labs Private Limited, Jaspack Industries Private Limited, and others.
- Revenue in INR (TTM)138.42bn
- Net income in INR17.75bn
- Incorporated1991
- Employees27.00k
- LocationMankind Pharma Ltd262, Okhla Industrial Estate, Phase-IIINEW DELHI 110020IndiaIND
- Phone+91 1 147476600
- Fax+91 1 146541382
- Websitehttps://www.mankindpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | MANKIND:NSI since announced | Transaction value |
|---|---|---|
| Shree Jee Laboratory Pvt Ltd | -11.41% | -- |
| Jaspack Industries Pvt Ltd | -11.41% | -- |
| JPR Labs Pvt Ltd | -11.41% | -- |
Data delayed at least 15 minutes, as of Feb 18 2026 10:23 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 441.07bn | 3.11k | 43.20 | -- | 40.50 | 11.60 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Laurus Labs Ltd | 67.22bn | 8.43bn | 547.09bn | 6.17k | 64.92 | -- | 41.76 | 8.14 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 565.66bn | 3.66k | 37.11 | -- | 35.38 | 8.29 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 575.35bn | 13.48k | 54.04 | -- | 35.61 | 3.49 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 142.53bn | 23.71bn | 652.41bn | 18.64k | 27.51 | -- | 23.21 | 4.58 | 198.32 | 198.32 | 1,192.01 | -- | -- | -- | -- | 7,645,478.00 | -- | 12.12 | -- | 17.53 | 64.05 | 60.06 | 17.00 | 14.69 | -- | 18.13 | -- | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 689.24bn | 9.11k | 19.77 | -- | 13.18 | 2.08 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 851.58bn | 27.00k | 48.04 | -- | 31.81 | 6.15 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 912.30bn | 27.92k | 18.47 | -- | 15.03 | 3.50 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.03tn | 19.98k | 20.69 | -- | 17.15 | 3.93 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
| Dr Reddy's Laboratories Ltd | 346.82bn | 55.68bn | 1.07tn | 26.94k | 19.23 | -- | 14.30 | 3.08 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.09tn | 30.31k | 23.89 | -- | 19.50 | 3.83 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
Data as of Feb 18 2026. Currency figures normalised to Mankind Pharma Ltd's reporting currency: Indian Rupee INR
10.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2025 | 6.82m | 1.65% |
| SBI Funds Management Ltd.as of 31 Dec 2025 | 6.20m | 1.50% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 2025 | 5.43m | 1.32% |
| Axis Asset Management Co. Ltd.as of 31 Jan 2026 | 5.36m | 1.30% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 2025 | 5.35m | 1.30% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 4.37m | 1.06% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 3.11m | 0.75% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 2.98m | 0.72% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 2.91m | 0.71% |
| Life Insurance Corporation of India (Investment Portfolio)as of 31 Dec 2025 | 2.55m | 0.62% |
More ▼
Data from 31 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
